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ABSTACT 
Objective: In previous work, Prifinium Bromide had been successfully formulated as oro-dispersible tablets. However, Prifinium Bromide, a 
quaternary ammonium compound, has a bitter taste; therefore, taste masking was necessary to produce acceptable oro-dispersible tablets and 
enhance patients' compliance.  
Methods: In this work, several attempts had been made to mask the bitterness of this drug. β-cyclodextrin inclusion complexes, solid dispersions of 
the drug in ethyl cellulose and methyl cellulose as well as loading the drug on Eudragit E100 have all been used. The selected granules were used to 
prepare oro-dispersible tablets and were evaluated.  
Results: Drug-Eudragit granules E3 prepared by mass extrusion method gave less than 10% of drug in simulated saliva fluid and almost complete 
release in simulated gastric fluid after 2 minutes. Therefore, it was used to prepare oro-dispersible tablets formulas. In vitro disintegration time of 
formula T2 was 45.5 ± 7.7 seconds showed a complete drug release of Prifinium Bromide in phosphate buffer (pH 6.8) and (94%) in SGF (pH 2.1).  
Conclusion: Loading of Prifinium Bromide on Eudragit E100 using mass extrusion method was the best method to overcome the disagreeable taste 
of the drug. They gave the least amount of drug released in simulated saliva fluid and passed the quality control tests of tablets after formulation as 
oro-dispersible tablets. They also gave good taste when tested in vivo. 
Keywords: Prifinium Bromide, Orodispersible tablets, Taste masking of active ingredient, Mass extrusion method, Eudragit E100, β - Cyclodextrine. 
 
INTRODUCTION 
Oro-dispersible tablets (ODTs) entered the market in the 1980s as 
an alternative to tablets and other conventional dosage forms. ODT 
is defined as a tablet that disperses or disintegrates in less than one 
minute in the mouth before swallowing. It results in quick 
dissolution and rapid absorption, which provide rapid onset of 
action. It also provides an advantage particularly for pediatric and 
geriatric populations who have difficulty in swallowing conventional 
tablets and capsules [1].  
There are some challenges in the formulation and production of 
successful ODTs like the fast disintegration, tablet strength and 
porosity, moisture sensitivity, amount of drug and the size of tablet 
in addition to the drug organoleptic properties like solubility, 
stability and taste [2]. For drugs having disagreeable taste, several 
taste masking techniques were introduced to overcome this 
problem. Addition of Sweeteners and flavors is a well known 
technique that uses artificial sweeteners instead of natural sugars. 
Saccharin Sodium, Aspartame, Sucralose have all been used as 
sweeteners [3]. 
Layering process is another technique used to overcome the 
disagreeable taste of active pharmaceutical ingredient (API) which 
involves deposition of serial layers of API onto the granules of an 
inert starter seeds such as sugar spheres or microcrystalline 
cellulose beads and using a polymer that’s usually not dissolve in pH 
of saliva [4],[5] 
Taste masking could also be achieved by granulation to decrease the 
surface area subjected to the taste buds. [6]. Spray drying, on the 
other hand, serves to coat the API particles with polymers as done 
by Dionysios, et al. Where Cetirizine HCl taste-masked ODT using 
Eudragit® RL30-D in different ratios were prepared using a 
fluidized bed coating machine. [7]. 
Complexation is used to mask the bitter taste of API by either 
decreasing its oral solubility on ingestion or decreasing the amount 
of drug particles exposed to taste buds thereby reducing the 
perception of bitter taste [8]. Cyclodextrin is one of the widely used 
complexing agent in masking taste by inclusion complexes [9]. 
Other approaches are coaservation phase separation [10], ion 
exchange resins [11], solid dispersions [12] and extrusion methodP 
P[13] have all been used to mask the disagreeable taste of the API. 
The aim of this study is to develop a successful method to cover the 
bitter taste of previously prepared Prifinium Bromide (PBr) ODT 
[14] by trying different techniques and the preparation of a taste 
masked ODT using a previously prepared formula.  
MATERIALS AND METHODS 
Prifinium Bromide, Mannitol, Ethocel, Aspartam, Sucralose, 
Magnesium Stearate and Mint flavor were kindly supplied by Hikma 
Pharmaceuticals. Eudragit E100 (Evonik industries, Germany). β- 
Cyclodextrin (Sigma- Adrich, USA).  
Avecil® HFE- 102 (AZ Chem for chemicals, Germany). VIVA Sol® 
Crosscarmellose sodium, VIVA Star®, HPMC hypromellose (JRS 
Pharma GMBH & Co., Germany). Banana and Pineapple flavors (Bell 
Flavors & fragrances, Germany).  
Compatibility study 
The compatibility of PBr with each of the used polymers 
(ethylcellulose, methylcellulose, mixture of ethyl and methyl 
cellolose, β-cyclodextrin and eudragit E100) has been investigated 
using differential scanning calorimetry (DSC). Each of the mentioned 
materials was scanned individually and then the PBr -polymer 
loaded granules were also analyzed. Each sample was weighed and 
subjected to heat range from 25°C to 300°C at a heating rate of 
10°C/min under a (80 ml/min) flow of nitrogen [15]. 
Preparation of taste-masked granules 
Preparation of inclusion complex  
Prifinium Bromide and β-cyclodextrin were mixed in the ratio (1:3) 
and (1:6) (w/w) ratio to prepare granules B1 and B2, respectively, 
as in table 1. Ethanol 50% added with continuous mixing until a 
suspension is formed. The solvent was evaporated under reduced 
pressure by using rotary evaporator for 45 minutes. After solvent 
evaporation, PBr - β- cyclodextrine granules obtained where stored 
in a desiccator for further use [16]. 
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Preparation of solid dispersion  
Solid dispersions were made by solvent evaporation method, in 
which different polymers, Avecil®, Ethocel, and Ethocel- Methocel 
mixtures were used in different ratios as follows: 
Prifinium bromide: Avicel® solid dispersion 
Prifinium Bromide and Avicel were mixed geometrically, then 
ethanol used as solvent added drop wise with continuous mixing 
using mortar and pestle. Few drops of polyvinylpyrrolidone (PVP) in 
ethanol 5% (w/v) was added as required. The resulted dispersion 
was then dried in oven for 30 minutes. The obtained granules were 
stored in a desiccator for further use. 
Prifinium bromide: ethocel solid dispersion 
Taste masked granules C1, C2 and C3 
Eudragit E100 was used to prepare taste masked granules of PBr by 
manual mass extrusion method [6],[10]. Fixed amount of drug was 
mixed geometrically with different amounts of powdered Eudragit 
E100 in (1:1, 1:3, 1:4 and 1:5) ratios in the mortar and pestle.  Then 
acetone was added to each mixture with continuous mixing. Thin gel 
was obtained from the mixture of the drug and Eudragit E100 which 
was manually extruded using a syringe.  
prepared by mixing PBr: 
Ethocel (1:0.1), (1:0.2) and (1:0.3) (w/w) ratio respectively as 
shown in table 1. Taste masked granules were prepared by same 
procedure of PBr -Avicel above. 
Prifinium bromide: Ethocel- Methocel Mixture solid dispersion 
Gupte and his colleagues proposed the use of water-soluble and water-
insoluble polymers in taste masking of highly water-soluble drugs [17]. 
In this study, D granules were prepared by same procedure above 
using Ethocel mixed with Methocel (50:50) to prepare (1:0.2) (w/w) 
ratio of PBr: Methocel- Ethocel mixture.  
Preparation of taste masked granules by Mass extrusion 
method  
After extrusion of the gel, acetone was removed by evaporation 
overnight and subsequently the solidified gel in the shape of strings 
was crushed into granules using a mortar and pestle and sieved to 
get a uniform size of drug- Eudragit E100 granules.  
Taste masked granules E1, E2, E3 and E4 containing PBr: Eudragit 
E100 in ratios (1:1, 1:3, 1:4 and 1:5) respectively, were obtained as 
shown in table 1. 
Evaluation of taste-masked granules 
Drug release in Simulated Saliva Fluid (SSF) 
Using phosphate buffer pH 6.2, 0.25 g of prepared granules were 
dissolved in 100 ml of phosphate buffer and filtered using syringe 
filter 0.45µm. Then, with appropriate dilution, the amount of drug 
release after 2, 5, 8 and 12 minutes was measured by UV 
spectroscopy at λmax 245nm. The percentage of drug release was 
calculated by equation1: 
Equation1: % Drug release = Amount of soluble drug in buffer
Total amount of drug in granules
∗ 100 
Drug release in Simulated Gastric Fluid (SGF) 
Using 0.1N HCl, adjusted with diluted NaOH, to prepare simulated 
gastric fluid (SGF) pH 2.1 the same method as in SSF was performed 
to evaluate drug release from the taste masked granules in acidic 
media. 
 
Table 1: Composition of Taste –Masked Granules 
Ingredients Taste Masked granules (mg) 
  A B1 B2 C1 C2 C3 D E1 E2 E3 E4 
PBr 15 15 15 15 15 15 15 15 15 15 15 
Eudragit E100               15 45 60 75 
Methocel              1.5         
Ethocel        1.5 3 4.5 1.5         
β-cyclodextrin    45 90                 
Avicel 80                     
 
Preparation of Orodispersible tablets 
The taste masked granules which gave the best evaluation results 
were weighed equivalent to 15 mg/tablet of PBr and were mixed 
with other diluents, superdisintegrant and sifted colloidal silicon 
dioxide (Aerosil™) in polyethylene bag and mixed manually for 
about 2 minutes. The flavor and sweetener were then added and 
mixed again for 2 minutes.  
The resulted mixture was passed through sieve no. 1.5 and the sifted 
materials were mixed again for about 2 minutes. Then, sifted 
magnesium stearate was added to the previous combination and 
mixed for about 1 minute. The percent of each ingredient was 
according to the standard formula prepared previously. The 
obtained powder blend was directly compressed into tablets on a 
rotary tablet press (Cadmach® compression machine, India) using 
9.7mm flat beveled bisected upper punch and plain lower punch. 
Evaluation of taste-masked tablets 
The tablets were evaluated for appearance, hardness, friability, 
content uniformity, disintegration and dissolution. Some 
modification on the formula has been made according to the results 
of some tests. Then stability of the best formula was tested in 
accelerated conditions (40±2 o
In vivo Disintegration time and taste evaluation 
C and 75±5% relative humidity RH). 
This test was performed on the selected formula using six healthy 
volunteers, who were informed precisely about the purpose of the 
study and the possible adverse effect of the API. Then three tablets 
were randomly chosen and the time required for complete 
disintegration of the tablet in the mouth, without biting and without 
drinking water, was measured. The volunteers were informed to spit 
the tablet and wash their mouth thoroughly.  
The taste was evaluated and assigned a numerical value in a 1 to 5 
scale according to the following scale 1: Distasteful. 2: Slightly 
Distasteful. 3: Fair. 4: Slightly Tasty. 5: Tasty [18]. 
RESULTS AND DISCUSSION 
Compatibility study 
During the preparation of complex, solid dispersion and the 
organogel and due to the use of solvent system each time, a 
possibility of chemical or physical interaction may arise. One of the 
known efficient methods to detect such an interaction is the DSC 
analysis. The following figures illustrate the DSC analysis of the taste 
masked granules that contain PBr and the polymers ethyl cellulose 
(Fig.1), mixture of ethyl and methyl cellulose (Fig.2), β-cyclodextrin 
(Fig.3), and Eudragit E100 (Fig.4). Thermograms show no additional 
peaks indication lack of chemical interaction between the drug and 
the polymers during granules preparation. 
Evaluation of taste masked granules in SSF 
The taste masked granules prepared using the above approaches in 
taste masking were evaluated in SSF (phosphate buffer pH 6.2) for 
drug release. The taste masked granules were designed to avoid 
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contact of the drug with taste buds; therefore a low drug release in 
saliva was desired. 
PBr - β- cyclodextrins inclusion complexes were prepared, (B1) and 
(B2) in a ratio of (1:3) and (1:6), respectively. β- cyclodextrins has a 
cone like structure that is able to incorporate a drug molecule within 
its cavity bonded by a Van der Waals forces forming inclusion 
complex that do not dissociate in saliva but are biodegradable in 




Fig. 1: DSC thermogram of Ethylcellulose (Ethocel), C1 (PBr-
ethylcellulose granules) and PBr 
 
 
Fig. 2: DSC thermogram of Methylcellulose (Methocel), D (PBr-
methylcellulose- ethylcellulose granules) and PBr. 
 
According to the evaluation of taste-masked granules shown in table 
2, the inclusion complexes were unstable or not completely formed 
which results in a rapid release of the drug. The taste masked 
granules B1 and B2 showed 48% and 97% drug release, 
respectively, in SSF after 2 minutes. This may be due to the fact that 
PBr has a strong hydrophilic area on the charged nitrogen atom that 
might be unable to be adapted by the inner surface of β- cyclodextrin 
cone that is a hydrophobic area. Further studies may be needed to 
investigate different possibilities of drug- β- cyclodextrins 
interaction. So far, this method was found to be ineffective to control 
the bitter taste of PBr. 
 
Fig. 3: DSC thermogram of β- cyclodextrin, B1 (PBr- β- 
cyclodextrin granules) and PBr 
 
 
Fig. 4: DSC thermogram of Eudragit E100, E3 (PBr-Eudragit 
E100 granules) and PBr 
 
Solid dispersions of PBr with the chosen polymers did not show 
efficient depletion of drug release in SSF. In all types prepared there 
was lack of sufficient bonding mechanisms between drug and the 
polymer which resulted in quick drug release in SSF. Thus, they 
would be inefficient to escape the mouth during and after 
disintegration of the tablet. This could be due to the fact that PBr is 
highly water soluble and may require an efficient coating technique 
to cover the particles completely and avoid contact with taste buds 
(Table2). 
PBr-Eudragit E100 granules prepared by mass extrusion method 1:4 
(E3) gave the least drug release in SSF (less than 10%) with higher 
release when less ratios were used, and no further decrease when 
higher ratios were used. (Table 2) That’s why E3 granules were 
chosen as the best granules that can control the bitter taste of PBr in 
mouth. While the formation of gel in mass extrusion method might 
result in much better drug dumping in the polymer network and 
also the dependency of solubility of Eudragit E100 on pH change 
from saliva (6.5-6.8) to acidic in stomach resulted in ability of these 




Table 2: Percent PBr Release from Taste Masked Granules in SSF. 
Time 
(min) 
 % PBr 
release 
from A 
 % PBr 
release 
from B1 



























0 0 0 0 0 0 0 0 0 0 0 0 
2 100 49 97 72 40 35 25 37 49 10 9 
5 100 49 95 99 76 66 63 48 48 15 19 
8 100 51 115 100 88 83 104 50 49 16 28 
12 100 52 105 99 90 85 95 50 50 20 29 
 
Evaluation of taste masked granules in Simulated Gastric Fluid 
(SGF) 
The behavior of E3 taste masked granules in stomach was detected 
by measuring the percentage of PBr release in SGF. The percentage 
of drug release in SGF and a comparison with the drug release in SSF 
is illustrated in fig.5. The results indicated a fast release 40 % of PBr 
in SGF, compared with only 9.6% of PBr in SSF after 2 minutes and 
more than 80% within 12 minutes. Therefore E3 taste masked 
granules was chosen to formulate taste masked PBr ODT. 
 
 
Fig. 5: Percentage of PBr release from E3 taste masked granules 
in SSF and in SGF. 
 
Physicochemical evaluation of the Taste masked PBr ODTs 
In vitro Disintegration time 
Formula T1 was prepared using E3 Taste masked granules with 
(1:4) ratio of (PBr: Eudragit E100) showed a long disintegration 
time of 160 ±5.1 seconds, which is not acceptable for ODT (Table 3) 
in comparison with 15 seconds of the standard formula with no 
taste masked granules. This may be due to the incorporation of PBr- 
Eudragit E100 granules, which contain polyvinyl pyrolidone (PVP) 
as a binding substance. After compression, there may be an increase 
in the bonding forces among particles causing a disruption of the 
porous structure and capillary characteristics of the compact 
powder. This may results in the long the disintegration time in 
formula T1.  
In order to decrease the disintegration time, T1 was compressed 
with a decrease in compression force. A shorter disintegration time 
of 50 ±5.6 seconds was achieved. However, the tablet yielded was 
too friable and did not pass the friability test.  
Therefore, Formula T2 with an increase in the percentage of 
crosscarmellose sodium (CCS) from 7.5% to 10% was prepared. Also 
other modification was made by increasing the flavor to enhance the 
taste acceptability. Disintegration time of T2 was 45.5 ± 7.7 seconds 
(Table 4) and with a hardness of 19.6N, tablets passed the friability 
test. Therefore, this formula was successful in meeting all the 
requirements of ODT and was further investigated for dissolution 
test, content uniformity, in vivo disintegration time test, in vivo taste 
evaluation and stability tests. 
Content uniformity, according to USP [20], of T2 gave accepted 
results with minimum 85.13%, maximum 94.07 %, mean = 88.56% 
of claimed label with SD = 2.89%. 























T1 15 15 60 47 47 2 2 10 2 200 
T2 15 20 60 42.5 42.5 2 6 10 2 200 
Standard 
Formula 
15 15 - 80 80 2 2 4 2 200 
 
Table 4: Evaluation of Taste masked ODTs. 
Formula Code Weight Uniformity  Hardness (N)  Friability In vitro disintegration time (sec) 
T1 Failed 37.3± 2.5  Pass 160.7± 5  
T2 Pass 20.6 ± 1.5  Pass 45±7 
Standard Formula Pass 35± 3.05  Pass 12.7± 0.58 
 
In vitro Drug Release (Dissolution test) 
Formula T2 was tested for in vitro dissolution to detect the release 
of PBr in pH 6.8 and in pH 2.1. After 10 minutes, it showed a 
complete drug release of PBr in phosphate buffer (pH 6.8) as 
demonstrated in fig. 6. Also in SGF (pH 2.1) high drug release was 
shown in same time (94%) as displayed in fig. 7. This indicates 
almost complete drug release in both simulated gastric and 
intestinal conditions. 
Stability study of Taste masked ODTs 
The results of stability study (formula T2) indicate that there was no 
decrease in PBr contents in Taste masked ODT compared to initial 
reading. These results indicate that PBr is stable during exposure to 
40 ± 2 °C and 75 ± 5 % RH for 31 days.  
And that loading of the drug on the polymer had no effect on the 
stability of tablets in these conditions for the specified time (Fig. 8). 
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Fig. 6: In vitro drug release of PBr from T2 taste masked ODT in 
phosphate buffer pH 6.8 
 
 
Fig. 7: In vitro drug release of PBr from formula T2 in SGF. 
 
 
Fig. 8: Percentage remaining of PBr in formula T2 after 
exposure to 40 ± 2 °C and 75 ± 5 % RH for 31 days. 
 
In vivo Disintegration time and taste evaluation 
The results of disintegration time of six volunteers were obtained 
and the average of 40.7± 10.7 seconds for complete disintegration 
was recorded which is considered acceptable time for orodispersible 
tablets. For taste evaluation, the volunteers had considered formula 
T2 as accepted taste with 25% Tasty, 62.5% Slightly Tasty and 
12.5% Fair taste with none scored Slightly Distasteful or Distasteful. 
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